Genetic variations in the CACNA1B gene, which encodes a key component of voltage-dependent calcium channels, affect the efficacy and response of neuroactive medications like antiepileptics and migraine treatments that target calcium channels. Due to these genetic differences, individuals may experience varying effects from these drugs, which is crucial for customizing personalized treatment plans.